Rakuten Medical is refueling with $100 million to support an ongoing Phase 3 trial for its photoimmunotherapy.
The Series F round includes $70 million in new funding and the conversion of $30 million in convertible …
Read More from Endpoints News
Rakuten Medical raises $100M for photoimmunotherapy platform
